Item 2. Management’s Discussion and Analysis
ITEM
2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
FORWARD-LOOKING
STATEMENTS
Certain
statements contained herein this report constitute “forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995 (the “1995 Reform Act”). Except for the historical information contained herein, this report
contains forward-looking statements (identified by words such as “estimate”, “project”, “anticipate”,
“plan”, “expect”, “intend”, “believe”, “hope”, “strategy” and
similar expressions), which are based on our current expectations and speak only as of the date made. These forward-looking statements
are subject to various risks, uncertainties and factors that could cause actual results to differ materially from the results anticipated
in the forward-looking statements.
Overview
The
Company, incorporated in the state of New York in May 1984 has conducted business in the name of Document Security Systems, Inc. On September
16, 2021, the board of directors approved an agreement and plan of merger with a wholly owned subsidiary, DSS, Inc. (a New York corporation,
incorporated in August 2020), for the sole purpose of effecting a name change from Document Security Systems, Inc. to DSS, Inc. This
change became effective on September 30, 2021. DSS, Inc. maintained the same trading symbol “DSS” and updated its CUSIP number
to 26253C 102.
DSS,
Inc. (together with its consolidated subsidiaries, referred to herein as “DSS,” “we,” “us,” “our”
or the “Company”), currently operates nine (9) distinct business lines with operations and locations around the globe. These
business lines are: (1) Product Packaging, (2) Biotechnology, (3) Direct, (4) Commercial Lending, (5) Securities and Investment Management,
(6) Alternative Trading (7) Digital Transformation (discontinued in 2023), (8) Secure Living (discontinued in 2023), and (9) Alternative
Energy (discontinued in 2023). Each of these business lines are in different stages of development, growth, and income generation.
Our
divisions, their business lines, subsidiaries, and operating territories: (1) Our Product Packaging line is led by Premier Packaging
Corporation, Inc. (“Premier”), a New York corporation. Premier operates in the paper board and fiber based folding carton,
consumer product packaging, and document security printing markets. It markets, manufactures, and sells sophisticated custom folding
cartons, mailers, photo sleeves and complex 3-dimensional direct mail solutions. Premier is currently located in its new facility in
Rochester, NY, and primarily serves the US market. (2) The Biotechnology business line was created to invest in or acquire companies
in the BioHealth and BioMedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition,
and treatment of neurological, oncological, and immune related diseases. This division is also targeting unmet, urgent medical needs,
and is developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.
(3) Direct Marketing, led by the holding corporation, Decentralized Sharing Systems, Inc. (“Decentralized”) provides services
to assist companies in the emerging growth “Gig” business model of peer-to-peer decentralized sharing marketplaces. Direct
Marketing’s products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific,
Middle East, and Eastern Europe. (4) Our Commercial Lending business division, driven by American Pacific Bancorp (“APB”),
is organized for the purposes of being a financial network holding company, focused on acquiring equity positions in (i) undervalued
commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia,
Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication
services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management,
SPAC (special purpose acquisition company) consulting services, and advisory capital raising services. (5) Securities and Investment
Management was established to develop and/or acquire assets in the securities trading or management arena, and to pursue, among other
product and service lines, broker dealers, and mutual funds management. Also in this segment is the Company’s real estate investment
trusts (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading
clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under
a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate.
(6) Alternative Trading was established to develop and/or acquire assets and investments in the securities trading and/or funds management
arena. Alternative Trading, in partnership with recognized global leaders in alternative trading systems, intends to own and operate
in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, and cryptocurrency
via an alternative trading platform using blockchain technology. The scope of services within this section is planned to include asset
issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, and UTO listings on a primary market(s), asset digitization/tokenization
(securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary
market(s). (7) Digital Transformation was established to be a Preferred Technology Partner and Application Development Solution for mid
cap brands in various industries including the direct selling and affiliate marketing sector. Digital improves marketing, communications
and operations processes with custom software development and implementation (discontinued in 2023). (8) The Secure Living division has
developed a plan for fully sustainable, secure, connected, and healthy living communities with homes incorporating advanced technology,
energy efficiency, and quality of life living environments both for new construction and renovations for single and multi-family residential
housing (discontinued in 2023). (9) The Alternative Energy group was established to help lead the Company’s future in the clean
energy business that focuses on environmentally responsible and sustainable measures. Alset Energy, Inc, the holding company for this
group, and its wholly owned subsidiary, Alset Solar, Inc., pursue utility-scale solar farms to serve US regional power grids and to provide
underutilized properties with small microgrids for independent energy (discontinued in 2023).
26
On
December 23, 2021, DSS purchased 50,000,000 shares at $0.06 per share of Sharing Services Global Corporation (“SHRG”) via
a private placement. With this purchase, DSS increased its ownership of voting shares from approximately 47% of SHRG to approximately
58%. On January 24, 2022, the Company exercised 50,000,000 warrants received as part of a consulting agreement with SHRG at the exercise
price of $0.0001, bring its ownership percentage of voting shares to approximately 65%. SHRG aims to build shareholder value by developing
or acquiring businesses that increase the Company’s product and services portfolio, business competencies and geographic reach.
Currently, the Company, through its subsidiaries, markets and distributes its health and wellness and other products primarily in the
United States, Canada, and the Asia Pacific region using a direct selling business model. The Company markets its products and services
through its independent sales force, using its proprietary websites, including: www.elevacity.com and www.thehappyco.com. The Company,
headquartered in Plano, Texas, was incorporated in the State of Nevada on April 24, 2015, and is an emerging growth company. The Company’s
Common Stock is traded, under the symbol “SHRG,” in the OTCQB Market, an over-the-counter trading platforms market operated
by OTC Markets Group Inc. On May 4, 2023, the Company distributed approximately 280 million shares of SHRG beneficially held by DSS and Decentralized
Sharing Systems in the form of a dividend to the shareholders of DSS common stock. Upon completion of this distribution, DSS will retain
an ownership interest in SHRG of approximately 7%. Immediately prior to this distribution, DSS owned approximately 81% of the issued and
outstanding common shares of SHRG. A s a result, SHRG, whose operations represented a significant
portion of our Direct Marketing segment, was deconsolidated from our consolidated financial statements effective as of May 1, 2023 (the
“Deconsolidation”). The consolidated statement of operations for the fiscal quarter ended September 30, 2023, therefore includes
one month of activity related to SHRG prior to the Deconsolidation. Subsequent to April 30, 2023 the assets and liabilities of SHRG are
no longer included within our consolidated balance sheets. Any discussions related to results, operations, and accounting policies associated
with SHRG refer to the periods prior to the Deconsolidation.
The
five reporting segments are as follows:
Premier
Packaging: (“Premier”) Premier Packaging Corporation provides custom packaging services and serves clients in the
pharmaceutical, nutraceutical, consumer goods, beverage, specialty foods, confections, photo packaging and direct marketing industries,
among others. The group also provides active and intelligent packaging and document security printing services for end-user customers.
In addition, the division produces a wide array of printed materials, such as folding cartons and paperboard packaging, security paper,
vital records, prescription paper, birth certificates, receipts, identification materials, entertainment tickets, secure coupons and
parts tracking forms. The division also provides resources and production equipment for our ongoing research and development of security
printing, brand protection, consumer engagement and related technologies.
Commercial
Lending: (“Commercial Lending”) through its operating company, American Pacific Bancorp, Inc. (“APB”)
is organized for the purposes of being a financial network holding company, focused providing commercial loans and on acquiring equity
positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the
United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related
to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment
leasing, problem asset management, SPAC (special purpose acquisition company) consulting, and advisory capital raising services. From
this financial platform, the Company shall provide an integrated suite of financial services for businesses that shall include commercial
business lines of credit, land development financing, inventory financing, third party loan servicing, and services that address the
financial needs of the world Gig Economy.
Biotechnology:
(“Biotech”) Impact BioMedical, Inc. targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical
science. Impact drives mission-oriented research, development, and commercialization of solutions for medical advances in human wellness
and healthcare. By leveraging technology and new science with strategic partnerships, Impact BioMedical provides advances in drug discovery
for the prevention, inhibition, and treatment of neurological, oncology and immuno-related diseases. Other technologies include
a breakthrough alternative sugar aimed to combat diabetes and functional fragrance formulations aimed at the industrial and medical industry.
27
The
business model of BioHealth and Impact BioMedical revolves around two methodologies – Licensing and Sales Distribution.
1)
Impact develops valuable and unique patented technologies which will be licensed to pharmaceutical, large consumer package goods
companies and venture capitalists in exchange for usage licensing and royalties.
2)
Impact utilizes the DSS ecosystem to leverage its sister companies that have in place distribution networks on a global scale. Impact
will engage in branded and private labelling of certain products for sales generation through these channels. This global distribution
model will give direct access to end users of Impact’s nutraceutical and health related products.
Securities
and Investment Management: (“Securities”) Securities was established to develop and/or acquire assets in the securities
trading or management arena, and to pursue, among other product and service lines, real estate investment funds, broker dealers, and
mutual funds management. This business sector has already established the following business lines and associated products and services:
●
REIT
Management Fund: In March 2020, DSS Securities formed AMRE (“American Medical REIT”) and its management company AAMI
(“AMRE Asset Management, Inc.) Through AAMI/AMRE, a medical real estate investment trust, fulfills community needs for quality
healthcare facilities while enabling care providers to allocate their capital to growth and investment in their contemporary clinical
and critical care businesses.
●
Sentinel
Brokers Company, Inc.: Sentinel primarily operates as a financial intermediary, facilitating institutional trading of municipal and corporate bonds
as well as preferred stock, and accelerates the trajectory of the DSS digital securities business.
●
DSS
AmericaFirst: DSS AmericaFirst is a suite of mutual funds managed by DSS Wealth Management. DSS AmericaFirst expects to expand
into numerous investment platforms including additional mutual funds, exchange-traded funds, unit investment trusts, and closed-end
funds. DSS AmericaFirst currently consists of four mutual funds that seek to outperform their respective benchmark indices by applying
a quantitative rules-based approach to security selection.
Direct
Marketing: (“Direct”) Through its holding company, Decentralized Sharing Systems, Inc. and its subsidiaries and partners,
provide an array of products and services which include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific
and Eastern Europe, through licensing agreements.
28
Results
of operations for the three months ended March 31, 2024, as compared to the three months ended March 31, 2023.
This
discussion should be read in conjunction with the financial statements and footnotes contained in this Quarterly Report and in our Annual
Report on Form 10-K for the year ended December 31, 2023.
Three
months ended
March
31, 2024
Three
months ended
March
31, 2023
%
Change
Printed products
$ 3,073,000
$ 6,130,000
-50 %
Rental income
400,000
1,685,000
-76 %
Net investment income
95,000
117,000
-19 %
Commission revenue
303,000
-
N/A
Direct marketing
-
3,994,000
-100 %
Total Revenue
$ 3,871,000
$ 11,926,000
-68 %
For
the three months ended March 31, 2024, total revenue decreased 68% as compared to the three months ended March 31, 2023. Revenues from
the sale of Printed products decreased 50% during three months ended March 31, 2024, as compared to the same period in 2023 due primarily
to orders expected to ship during the 4 th quarter 2022 being pushed to the 1st quarter 2023. The decreases in Rental income
of 76% for the three months ended March 31, 2024 as compared to the three months ended March 31, 2023 is driven by the tenants at AMRE
LifeCare being unable to make rental payments in 2024. The decreases in Net investment income approximating 19% for the three months
ended March 31, 2024 as compared to the three months ended March 31, 2023 is due to a number of loans made going on non-accrual as borrowers
have struggled to make expect payments. The Company’s Direct Marketing revenues decreased three months ended March 31, 2024 as
compared to the three months ended March 31, 2023 is due to the Deconsolidation of SHRG as described in Note 1.
29
Three
months ended
March
31, 2024
Three
months ended
March
31, 2023
%
Change
Cost of revenue
Printed products
$ 2,767,000
$ 4,660,000
-41 %
Securities
1,744,000
2,537,000
-31 %
Biotechnology
10,000
-
N/A
Commercial lending
469,000
-
N/A
Direct marketing
-
1,290,000
-100 %
Other
-
46,000
-100 %
Sales, general and administrative
compensation
1,229,000
5,140,000
-76 %
Professional fees
991,000
561,000
77 %
Sales and marketing
493,000
1,810,000
-73 %
Rent and utilities
136,000
236,000
-42 %
Research and development
50,000
179,000
-72 %
Other operating expenses
662,000
1,047,000
-37 %
Total
costs and expenses
$ 8,551,000
$ 17,506,000
-51 %
Costs
of revenue include all direct costs of the Company’s printed products, including its packaging and printing sales and its direct
marketing sales, materials, direct labor, transportation, and manufacturing facility costs. In addition, this category includes all direct
costs associated with the Company’s technology sales, services and licensing including hardware and software that are resold, third-party
fees, and fees paid to inventors or others because of technology licenses or settlements, if any. Cost of revenue for our Securities
operating segments is comprised mainly of our REIT line of business and includes all direct cost associated with the maintenance and
upkeep of the related facilities, depreciation, amortization, and the costs to acquire the facilities. Our Commercial Lending operating
segment has costs of revenue associated with the impairment of notes receivable for those amounts at risk of collection. Total costs
of revenue decreased 42% for three months ended March 31, 2024 as compared to 2023 is primarily related to the Deconsolidation of SHRG
as described in Note 1. Also, cost of revenue decreased at Premier for the same time period due to the decrease in product shipped.
Sales,
general and administrative compensation costs, excluding stock-based compensation, decreased 76% for three months ended March 31,
2024 as compared to 2023 is primarily related to the Deconsolidation of SHRG as described in Note 1.
Professional
fees increased 77% for three months ended March 31, 2024 as compared to 2023 due primarily to primarily due to increases in
accounting fees for tax return preparation as well as audit fees associated with the required SEC reporting for ImpactBio offset by
settlement of disputed legal fees of approximately $743,000 during the first quarter of 2023.
Sales
and marketing which include internet and trade publication advertising, travel and entertainment costs, sales-broker commissions,
and trade show participation expenses. Sales and marketing decreased 73% three months ended March 31, 2024 as compared to 2023 due primarily
to the Deconsolidation of SHRG as described in Note 1.
Rent
and utilities decreased 42% primarily due to end of the lease in Tennessee for AMRE office space and California for the Company’s
DSS Wealth Management subsidiary as well as the deconsolidation of SHRG. primarily due to end of the lease in Tennessee for AMRE office
space and California for the Company’s DSS Wealth Management subsidiary as well as the deconsolidation of SHRG.
Research
and development costs represent costs consisting primarily of independent, third-party testing of the various properties of each
technology the Company owns possesses as well as research on new technologies. These costs decreased 72% the three months ended March
31, 2024 as compared to March 31, 2023, due primarily to the cessation of the Company’s research and development contract with
GRDG at the end of 2023.
Other
operating expenses consist primarily of equipment maintenance and repairs, office supplies, IT support, and insurance costs.
During the three months ended March 31, 2024 as compared to March 31, 2023, the fluctuation is due primarily to the Deconsolidation
of SHRG as described in Note 1.
30
Other
Income (Expense)
Three
months ended
March
31, 2024
Three
months ended
March
31, 2023
%
Change
Interest Income
$ 107,000
$ 130,000
-18 %
Dividend Income
-
4,000
-100 %
Interest Expense
(48,000 )
(249,000 )
-81 %
Other Income (expense)
21,000
(65,000 )
-132 %
Loss on investments
(189,000 )
(2,869,000 )
-93 %
Loss on equity method investment
(1,000 )
(4,000 )
-75 %
Provision for loan losses
(294,000 )
-
N/A
Total
other expense
$ (404,000 )
$ (3,053,000 )
87 %
Interest
income is recognized on the Company’s money markets, and a portion of notes receivable, identified in Note 4.
Other
income (expense) for the three months ended March 31, 2024 as compared to 2023 increased 132% due primarily to cost incurred in 2023
regarding the Company’s distribution agreement with BioMed Technologies.
Interest
expenses decreased 81% during the three months ended March 31, 2024, as compared to the same period in 2023,
due to decreasing debt balances.
Loss
on investments consists of net realized losses on marketable securities which are recognized as the difference between the purchase
price and sale price of the common stock investment, and net unrealized losses on marketable securities which are recognized on the change
in fair market value on our common stock investment.
Loss
on equity method investment is the Company’s prorated portion of earnings on its investments treated under the equity method
of account for the three months ended March 31, 2024 as compared to 2023
Net
Loss
Three months ended
March 31, 2024
Three months ended March 31, 2023
% Change
Loss from operations
$ (5,109,000 )
$ (8,633,000 )
41 %
For
the three months ended March 31, 2024 the Company recorded net losses of $5,109,000 as compared to net losses of $8,633,000 for the same
period in 2023. The decrease in net loss is driven by the Deconsolidation of SHRG as described in Note 1.
31
LIQUIDITY
AND CAPITAL RESOURCES
The
Company has historically met its liquidity and capital requirements primarily through the sale of its equity securities and debt financing.
As of March 31, 2024 the Company had cash of approximately $9.3 million. As of March 31, 2024, the Company believes that it has sufficient
cash to meet its cash requirements for at least the next 12 months from the filing date of this Annual Report. In addition, the Company
believes that it will have access to sources of capital from the sale of its equity securities and debt financing. The deconsolidation
of SHRG and sale of HWH Holdings, Inc, two companies with historical losses, also is expected to improve future cash flows.
Cash
Flow from Continuing Operating Activities
Net
cash used from operating activities was $2,150,000 for the three months ended March 31, 2024 as compared to $14,199,000 for three months
ended March 31, 2023. This fluctuation is driven by decreases in net loss approximating $3,524,000.
Cash
Flow from Investing Activities
Net
cash provided by investing activities was $5,097,000 for the three months ended March 31, 2024 as compared to net cash provided by investing
activities of $11,537,000 for the three months ended March 31, 2023. This fluctuation is driven by the sale of marketable securities
approximating $11,330,000 during 2023 versus $1,160,000 during 2024. This is offset by receipts on Notes receivable of $3,971,000 in
2024 versus $764,000 in 2023.
Cash
Flow from Financing Activities
Net
cash used from financing activities was $310,000 for the three months ended March 31, 2024 as compared to net cash used from financing
activities of $2,896,000 for the three months ended March 31, 2023. This variance is driven by payments toward long term debt of $1,399,000
in 2024 versus $4,002,000 in 2023.
Off-Balance
Sheet Arrangements
We
do not have any material off-balance sheet arrangements that have, or are reasonably likely to have, an effect on our financial condition,
financial statements, revenues, or expenses.
Critical
Accounting Policies and Estimates
The
preparation of financial statements and related disclosures in conformity with U.S. GAAP requires management to make judgments, assumptions
and estimates that affect the amounts reported in our financial statements and accompanying notes. The financial statements as of December
31, 2023, describe the significant accounting policies and methods used in the preparation of the financial statements. There have been
no material changes to such critical accounting policies as of the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.
32